NIBR chief Jay Bradner tells Scrip that the Swiss major's focus is on developing first in class therapies rather than 'fast-follower' research seen across the biopharma sector.
Novartis AG has presented a detailed look into both early and late-stage assets which it believes could produce 25 potential blockbusters.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.
The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.
